VA

Venrock Adviser, LLC

Momentum followerQuality / disciplined sizing

Total reported value

$2.7B

Reporting period: 2026-03-31 · Number of holdings: 33

Venrock Adviser, LLC disclosed 33 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.7B and a quarterly turnover rate of 41.3%.

Personality snowflake

Concentration
41.5
Portfolio Stability
41.28
Momentum/Contrarian
100
Sector conviction
0
Diversification
66
Sizing Uniformity
84.19

Recent moves

  • Add ERAS

    -8.3%　$198.6M

  • Trim APGE

    0.0%　$73.8M

  • Trim VRDN

    0.0%　-$44.9M

  • Add DNTH

    +18.0%　$57.8M

  • Trim CTMX

    -35.9%　-$19.4M

  • Add ORKA

    0.0%　$77.7M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1APGEApogee Therapeutics INCStock-Other26.68%-4.99%—
2ERASErasca INCStock-Other9.89%+6.61%-8.26%
3ORKAOruka Therapeutics INCStock-Other7.60%+1.39%—
4SYRESpyre Therapeutics INCStock-Other6.94%+0.98%—
54XC1Kalvista Pharmaceuticals INCStock-Other4.86%-0.51%-3.78%
6DNTHDianthus Therapeutics INCStock-Other3.70%+1.66%+18.00%
7DMRADamora Therapeutics INCStock-Other3.48%+3.48%NEW
8OCULOcular Therapeutix INCStock-Other3.27%-1.12%+41.44%
9COGTCogent Biosciences INCStock-Other2.87%-0.64%—
10VRDNViridian Therapeutics INCStock-Other2.83%-3.14%—
11SVRASavara INCStock-Other2.80%-1.29%—
12ELVNEnliven Therapeutics INCStock-Other2.53%+0.08%-46.49%
13ORICOric Pharmaceuticals INCStock-Other2.04%-0.25%-23.90%
14VORVor Biopharma INCStock-Other2.03%+0.77%+56.49%
15MAZEMaze Therapeutics INCStock-Other1.78%-1.39%+3.45%
16CTMXCytomx Therapeutics INCStock-Other1.75%-1.52%-35.85%
17JBIOJade Biosciences INCStock-Other1.69%-0.76%—
18DYNDyne Therapeutics INCStock-Other1.47%-0.63%—
19✓ Crescent Biopharma INC.Stock-Other1.46%+0.21%—
20✓ Zura Bio LTDStock-Other1.43%+0.05%+20.39%
21RLMDRelmada Therapeutics INCStock-Other1.26%+1.26%NEW
22✓ Engene Holdings INCStock-Other1.21%-0.92%—
23TENXTenax Therapeutics INCStock-Other1.00%+1.00%NEW
24ANLAdlai Nortye Ltd-adrStock-Other0.83%+0.83%NEW
25IPSCCentury Therapeutics INCStock-Other0.73%+0.73%NEW
26CGEMCullinan Therapeutics INCStock-Other0.73%+0.02%—
27HELPCybin INCStock-Other0.69%-0.86%+0.30%
28SRZNSurrozen INCStock-Other0.69%-0.02%—
29SEPNSepterna INCStock-Other0.45%-0.39%-17.15%
30KRROKorro Bio INCStock-Other0.43%+0.43%NEW
31ANROAlto Neuroscience INCStock-Other0.42%+0.42%NEW
32ARTVArtiva Biotherapeutics INCStock-Other0.39%+0.05%—
33XFORX4 Pharmaceuticals INCStock-Other0.05%+0.05%NEW

Holding changes this quarter

Venrock Adviser, LLC's most significant position changes for 2026-03-31: New buy: Damora Therapeutics INC (DMRA); New buy: Relmada Therapeutics INC (RLMD); Sold out: Upstream Bio INC (UPB); New buy: Tenax Therapeutics INC (TENX); New buy: Adlai Nortye Ltd-adr (ANL).

Position changes disclosed by Venrock Adviser, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1ERASErasca INC+6.6%-8.26%Trim
2DNTHDianthus Therapeutics INC+1.7%+18.00%Add
3ORKAOruka Therapeutics INC+1.4%—Unchanged
4SYRESpyre Therapeutics INC+1%—Unchanged
5VORVor Biopharma INC+0.8%+56.49%Add
6✓ Crescent Biopharma INC.+0.2%—Unchanged
7ELVNEnliven Therapeutics INC+0.1%-46.49%Trim
8✓ Zura Bio LTD+0.1%+20.39%Add
9ARTVArtiva Biotherapeutics INC+0.1%—Unchanged
10CGEMCullinan Therapeutics INC0%—Unchanged
11SRZNSurrozen INC0%—Unchanged
12ORICOric Pharmaceuticals INC-0.3%-23.90%Trim
13SEPNSepterna INC-0.4%-17.15%Trim
144XC1Kalvista Pharmaceuticals INC-0.5%-3.78%Trim
15DYNDyne Therapeutics INC-0.6%—Unchanged
16COGTCogent Biosciences INC-0.6%—Unchanged
17JBIOJade Biosciences INC-0.8%—Unchanged
18HELPCybin INC-0.9%+0.30%Add
19✓ Engene Holdings INC-0.9%—Unchanged
20OCULOcular Therapeutix INC-1.1%+41.44%Add
21SVRASavara INC-1.3%—Unchanged
22MAZEMaze Therapeutics INC-1.4%+3.45%Add
23CTMXCytomx Therapeutics INC-1.5%-35.85%Trim
24VRDNViridian Therapeutics INC-3.1%—Unchanged
25APGEApogee Therapeutics INC-5%—Unchanged
26DMRADamora Therapeutics INC—NEWNew buy
27RLMDRelmada Therapeutics INC—NEWNew buy
28UPBUpstream Bio INC—EXITSold out
29TENXTenax Therapeutics INC—NEWNew buy
30ANLAdlai Nortye Ltd-adr—NEWNew buy
31IPSCCentury Therapeutics INC—NEWNew buy
32KRROKorro Bio INC—NEWNew buy
33ANROAlto Neuroscience INC—NEWNew buy
34XFORX4 Pharmaceuticals INC—NEWNew buy
35✓ Casi Pharmaceuticals INC—EXITSold out

FAQ

What is Venrock Adviser, LLC and what type of investor is it?
Venrock Adviser, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $2.7B, spread across 33 disclosed positions.
What are Venrock Adviser, LLC's largest equity positions?
Based on the latest 13F filing, Venrock Adviser, LLC's top holdings by market value are: 1. Apogee Therapeutics INC (APGE) — $714.9M (26.7%) 2. Erasca INC (ERAS) — $265.1M (9.9%) 3. Oruka Therapeutics INC (ORKA) — $203.5M (7.6%) 4. Spyre Therapeutics INC (SYRE) — $185.9M (6.9%) 5. Kalvista Pharmaceuticals INC (4XC1) — $130.3M (4.9%)
What changes did Venrock Adviser, LLC make in its most recent portfolio filing?
In the latest reported quarter, Venrock Adviser, LLC made 22 notable position adjustments: 8 new positions were initiated, 6 existing holdings were added to, 6 positions were partially reduced, and 2 were completely exited. The largest of these moves: New buy: Damora Therapeutics INC (DMRA); New buy: Relmada Therapeutics INC (RLMD); Sold out: Upstream Bio INC (UPB); New buy: Tenax Therapeutics INC (TENX); New buy: Adlai Nortye Ltd-adr (ANL)
What sectors does Venrock Adviser, LLC focus on?
Sector breakdown data is not yet available for Venrock Adviser, LLC. Check back after the next 13F processing cycle.